Stocks
Agios Pharmaceuticals Financial Statements (AGIO) |
||||||||||
| Agios Pharmaceuticalssmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 19.02.2020 | 25.02.2021 | 24.02.2022 | 23.02.2023 | 15.02.2024 | 31.10.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 117.9 | 203.2 | 0.000 | 14.2 | 26.8 | 32.9 | |||
| Operating Income, bln rub | -426.3 | -316.1 | -378.4 | -389.0 | -391.5 | -407.0 | ||||
| EBITDA, bln rub | ? | -394.9 | -326.1 | -337.7 | -380.5 | -384.9 | 702.6 | |||
| Net profit, bln rub | ? | -396.6 | -335.2 | 1 605 | -74.6 | -352.1 | 674.3 | |||
| OCF, bln rub | ? | -370.6 | -290.8 | -407.3 | -309.5 | -296.1 | -329.2 | |||
| CAPEX, bln rub | ? | 12.2 | 14.9 | 5.74 | 4.88 | 0.999 | 0.952 | |||
| FCF, bln rub | ? | -382.8 | -305.7 | -413.1 | -314.4 | -297.1 | -330.1 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 542.9 | 516.5 | 378.4 | 401.6 | 408.8 | 432.0 | ||||
| Cost of production, bln rub | 1.32 | 2.81 | 18.8 | 1.70 | 9.50 | 7.84 | ||||
| R&D, bln rub | 410.9 | 367.5 | 257.0 | 279.9 | 288.9 | 291.6 | ||||
| Interest expenses, bln rub | 0.000 | 17.8 | 0.000 | 12.8 | 0.000 | 0.000 | ||||
| Assets, bln rub | 890.7 | 853.0 | 1 438 | 1 239 | 937.1 | 1 792 | ||||
| Net Assets, bln rub | ? | 640.5 | 399.5 | 1 292 | 1 101 | 811.0 | 1 627 | |||
| Debt, bln rub | 113.7 | 105.2 | 97.1 | 85.7 | 72.0 | 60.8 | ||||
| Cash, bln rub | 564.9 | 670.5 | 1 286 | 1 097 | 776.9 | 1 005 | ||||
| Net debt, bln rub | -451.2 | -565.3 | -1 189 | -1 011 | -704.9 | -943.9 | ||||
| Ordinary share price, rub | 47.8 | 43.3 | 32.9 | 28.1 | 22.3 | 21.0 | ||||
| Number of ordinary shares, mln | 60.0 | 69.0 | 60.4 | 54.8 | 55.7 | 56.9 | ||||
| Market cap, bln rub | 2 865 | 2 990 | 1 987 | 1 538 | 1 239 | 1 195 | ||||
| EV, bln rub | ? | 2 414 | 2 424 | 798 | 527 | 534 | 251 | |||
| Book value, bln rub | 641 | 400 | 1 292 | 1 101 | 811 | 1 627 | ||||
| EPS, rub | ? | -6.61 | -4.86 | 26.5 | -1.36 | -6.33 | 11.8 | |||
| FCF/share, rub | -6.38 | -4.43 | -6.83 | -5.74 | -5.34 | -5.80 | ||||
| BV/share, rub | 10.7 | 5.79 | 21.4 | 20.1 | 14.6 | 28.6 | ||||
| EBITDA margin, % | ? | -334.9% | -160.5% | -2 672% | -1 435% | 2 137% | ||||
| Net margin, % | ? | -336.4% | -165.0% | -523.6% | -1 313% | 2 051% | ||||
| FCF yield, % | ? | -13.4% | -10.2% | -20.8% | -20.4% | -24.0% | -27.6% | |||
| ROE, % | ? | -61.9% | -83.9% | 124.2% | -6.77% | -43.4% | 41.5% | |||
| ROA, % | ? | -44.5% | -39.3% | 111.6% | -6.02% | -37.6% | 37.6% | |||
| P/E | ? | -7.22 | -8.92 | 1.24 | -20.6 | -3.52 | 1.77 | |||
| P/FCF | -7.48 | -9.78 | -4.81 | -4.89 | -4.17 | -3.62 | ||||
| P/S | ? | 24.3 | 14.7 | 108.0 | 46.2 | 36.4 | ||||
| P/BV | ? | 4.47 | 7.48 | 1.54 | 1.40 | 1.53 | 0.73 | |||
| EV/EBITDA | ? | -6.11 | -7.43 | -2.36 | -1.39 | -1.39 | 0.36 | |||
| Debt/EBITDA | 1.14 | 1.73 | 3.52 | 2.66 | 1.83 | -1.34 | ||||
| R&D/CAPEX, % | 3 376% | 2 465% | 4 476% | 5 735% | 28 919% | 30 632% | ||||
| CAPEX/Revenue, % | 10.3% | 7.34% | 34.3% | 3.72% | 2.90% | |||||
| Agios Pharmaceuticals shareholders | ||||||||||
